Efficacy and cost-benefit analysis of branded versus generic tacrolimus, administered in combination with mycophenolate mofetil + prednisone, in renal transplant recipients in the USA

Trial Profile

Efficacy and cost-benefit analysis of branded versus generic tacrolimus, administered in combination with mycophenolate mofetil + prednisone, in renal transplant recipients in the USA

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 May 2011

At a glance

  • Drugs Tacrolimus (Primary) ; Mycophenolate mofetil; Prednisone
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 May 2011 New trial record
    • 04 May 2011 Results presented at the American Transplant Congress -- 11th Joint Congress of the American Society of Transplant Surgeons and the American Society of Transplantation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top